Wall Street brokerages expect that Chimerix Inc (NASDAQ:CMRX) will report sales of $810,000.00 for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Chimerix’s earnings. The highest sales estimate is $1.00 million and the lowest is $500,000.00. Chimerix reported sales of $1.98 million during the same quarter last year, which indicates a negative year-over-year growth rate of 59.1%. The firm is expected to report its next earnings report on Thursday, March 1st.
According to Zacks, analysts expect that Chimerix will report full-year sales of $810,000.00 for the current year, with estimates ranging from $2.65 million to $3.65 million. For the next fiscal year, analysts anticipate that the company will post sales of $3.75 million per share, with estimates ranging from $1.00 million to $6.25 million. Zacks’ sales calculations are a mean average based on a survey of research analysts that cover Chimerix.
Chimerix (NASDAQ:CMRX) last issued its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.37) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.43) by $0.06. Chimerix had a negative net margin of 1,440.67% and a negative return on equity of 26.00%. The business had revenue of $0.90 million for the quarter, compared to analysts’ expectations of $0.81 million.
In related news, insider Linda M. Richardson sold 19,833 shares of the company’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $4.47, for a total value of $88,653.51. The transaction was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 10.50% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Citadel Advisors LLC raised its holdings in shares of Chimerix by 131.8% in the 3rd quarter. Citadel Advisors LLC now owns 165,490 shares of the biopharmaceutical company’s stock worth $869,000 after acquiring an additional 94,108 shares during the last quarter. Nationwide Fund Advisors raised its holdings in shares of Chimerix by 70.3% in the 3rd quarter. Nationwide Fund Advisors now owns 60,567 shares of the biopharmaceutical company’s stock worth $318,000 after acquiring an additional 24,994 shares during the last quarter. Schwab Charles Investment Management Inc. raised its holdings in shares of Chimerix by 112.3% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 200,891 shares of the biopharmaceutical company’s stock worth $1,055,000 after acquiring an additional 106,267 shares during the last quarter. Russell Investments Group Ltd. acquired a new stake in shares of Chimerix in the 3rd quarter worth about $428,000. Finally, State Street Corp raised its holdings in shares of Chimerix by 7.3% in the 2nd quarter. State Street Corp now owns 828,936 shares of the biopharmaceutical company’s stock worth $4,515,000 after acquiring an additional 56,600 shares during the last quarter. Institutional investors own 70.36% of the company’s stock.
Chimerix (NASDAQ CMRX) opened at $4.70 on Friday. Chimerix has a fifty-two week low of $4.17 and a fifty-two week high of $6.64. The firm has a market cap of $222.45, a PE ratio of -3.29 and a beta of 1.42.
Chimerix Company Profile
Chimerix, Inc is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.